GetTopicDetailResponse(id=5c302825aa, topicName=Asciminib, introduction=Asciminib, content=null, image=null, comments=2, allHits=1463, url=https://h5.medsci.cn/topic?id=2825, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=97841, tagList=[TagDto(tagId=97841, tagName=Asciminib)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2209286, encodeId=eeba220928616, content=<a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a> <a href='/topic/show?id=5c302825aa' target=_blank style='color:#2F92EE;'>#Asciminib#</a>, objectTitle=STAMP抑制劑Asciminib治療初治CML的3期研究結果, objectType=article, longId=829565, objectId=4d648295652b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240610/1718034049198_5579292.jpg, objectUrl=/article/show_article.do?id=4d648295652b, replyNumber=0, likeNumber=97, createdTime=2024-06-10, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4d648295652b, moduleTitle=STAMP抑制劑Asciminib治療初治CML的3期研究結果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4d648295652b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1733569, encodeId=1f841e335691a, content=<a href='/topic/show?id=5c302825aa' target=_blank style='color:#2F92EE;'>#Asciminib#</a>, objectTitle=FDA 批準Scemblix（asciminib）治療慢性粒細胞白血病, objectType=article, longId=219579, objectId=ee952195e949, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee952195e949, replyNumber=0, likeNumber=123, createdTime=2022-07-11, rootId=0, userName=yanghan, userId=0f9c33763742, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee952195e949, moduleTitle=FDA 批準Scemblix（asciminib）治療慢性粒細胞白血病, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ee952195e949)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1733568, encodeId=f7e71e335685e, content=<a href='/topic/show?id=5c302825aa' target=_blank style='color:#2F92EE;'>#Asciminib#</a>, objectTitle=NEJM：Asciminib二線治療費城染色體陽性白血病, objectType=article, longId=184673, objectId=05d51846e3ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05d51846e3ec, replyNumber=0, likeNumber=90, createdTime=2020-02-15, rootId=0, userName=yanghan, userId=0f9c33763742, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05d51846e3ec, moduleTitle=NEJM：Asciminib二線治療費城染色體陽性白血病, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=05d51846e3ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
